Sun Pharma Entered into a License Agreement with Philogen to Commercialize Nidlegy for Skin Cancers
Shots:
- Sun Pharma to get an exclusive right to commercialize Nidlegy (developed by Philogen), a new anti-cancer biopharmaceutical drug for skin cancers in the territories of EU, Australia & New Zealand along with being responsible for commercialization activities
- Philogen will hold IP rights for Nidlegy in other territories & indications excl. skin cancer. Post-commercialization costs will be split equally b/w 2 companies in a ratio (50:50)
- Philogen intends to complete pivotal clinical studies for Nidlegy in the EU & seek marketing authorization from the regulatory authorities, will also be involved in the manufacture of commercial supplies. Nidlegy is being studied in the P-III trials for melanoma & non-melanoma skin cancers
Ref: PR Newswire | Image: Sun Pharma
Related News:- Sun Pharmaceutical’ Sezaby Receives the US FDA’s Approval for the Treatment of Neonatal Seizures
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
